Repositioning Candidate Details
| Candidate ID: | R0431 |
| Source ID: | DB01162 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Terazosin |
| Synonyms: | 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; Terazosin; Terazosine |
| Molecular Formula: | C19H25N5O4 |
| SMILES: | COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1 |
| Structure: |
|
| DrugBank Description: | Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate. |
| CAS Number: | 63590-64-7 |
| Molecular Weight: | 387.4329 |
| DrugBank Indication: | Terazosin is indicated for use in treating symptomatic benign prostatic hyperplasia and hypertension. |
| DrugBank Pharmacology: | Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocker. |
| DrugBank MoA: | Terazosin is selective for alpha-1-adrenoceptors but not their individual subtypes. Inhibition of these alpha-1-adrenoceptors results in relaxation of smooth muscle in blood vessels and the prostate, lowering blood pressure and improving urinary flow. Smooth muscle cells accounts for roughly 40% of the volume of the prostate and so their relaxation reduces pressure on the urethra. It has also been shown that catecholamines induce factors responsible for mitogenesis and alpha-1-adrenergic receptor blockers inhibit this effect. A final long term mechanism of terazosin and other alpha-1-adrenergic receptor blockers is the induction of apoptosis of prostate cells. Treatment with terazosin enhances the expression of transforming growth factor beta-1 (TGF-beta1), which upregulates p27kip1, and the caspase cascade. |
| Targets: | Alpha-1A adrenergic receptor antagonist; Alpha-1B adrenergic receptor antagonist; Alpha-1D adrenergic receptor antagonist; Potassium voltage-gated channel subfamily H member 2 inhibitor; Potassium voltage-gated channel subfamily H member 6 inhibitor; Potassium voltage-gated channel subfamily H member 7 inhibitor; Transforming growth factor beta-1 inducer |
| Inclusion Criteria: | Therapeutic strategy associated |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I12 | 10763 | Hypertension | An artery disease characterized by chronic elevated blood pressure in the arteries. https://en.wikipedia.org/wiki/Hypertension, https://www.ncbi.nlm.nih.gov/pubmed/24352797 | disease of anatomical entity/ cardiovascular system disease/vascular disease/ artery disease | Details |